Literature DB >> 2614701

Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects.

C K Shim1, J S Hong.   

Abstract

Inter- and intrasubject variations of ranitidine pharmacokinetics were examined following oral administration of ranitidine tablets (150 mg as base) under controlled conditions at a timed interval of one week (periods I and II) to 12 healthy male subjects. Significant secondary peaks in the plasma concentration-time curves were observed in all subjects in both periods. The first peak occurred at 0.5 to 2.5 h and the second peak at 3 to 6 h after the dosing. There were great variations in the plasma concentration-time profiles among subjects; for example, the area under the plasma concentration-time curve from time 0 to 12 h (AUC0-12) varied from 1905 to 5672 micrograms.h/mL. But bioavailability parameters of period I, such as maximum concentration of the first and second plasma peak (Cmax 1 and Cmax 2, respectively), time to first peak (tmax 1), AUC0-12, and AUC from time zero to infinity (AUC0-infinity), were correlated significantly with those of period II. These results suggest that the intrasubject variation of ranitidine pharmacokinetics is usually small over at least one week under the controlled conditions of this study, in spite of its great intersubject variation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2614701     DOI: 10.1002/jps.2600781204

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine.

Authors:  Abdul W Basit; Fridrun Podczeck; J Michael Newton; Wendy A Waddington; Peter J Ell; Larry F Lacey
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 4.  Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives.

Authors:  Suresh P Sulochana; Muzeeb Syed; Devaraj V Chandrasekar; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

5.  The influence of gastrointestinal transit on drug absorption in healthy volunteers.

Authors:  S A Riley; F Sutcliffe; M Kim; M Kapas; M Rowland; L A Turnberg
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

6.  Absorption and disposition of a new antiarrhythmic agent bidisomide in man.

Authors:  C S Cook; G B Ames; M E Smith; K G Kowalski; A Karim
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

7.  Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.

Authors:  K S Reynolds; M H Song; W D Heizer; C B Burns; D A Sica; K L Brouwer
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

8.  Pharmacokinetics of a novel antiarrhythmic drug, actisomide.

Authors:  C S Cook; L F Rozek; J Stolzenbach; S Anderson; G L Schoenhard; A Karim
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

9.  Gastrointestinal transit and distribution of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

10.  Regional gastrointestinal absorption of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.